Patients Capital Management LLC
@PCM_bio
Followers
2K
Following
4K
Media
39
Statuses
2K
Long Only Biotech | tweets not investment advice | #PCM
New York, NY
Joined May 2023
25% in $vrna today into the close. Lot of noise the last few months, but one thing hasn’t changed. Pharma has a math problem and $vrna is uniquely positioned to solve some of it. If true, good move by $MRK. Stock should start to resume upward momentum. To Rob Davis: We can work.
Comfortable sharing now because I don’t think the internet has the courage to chase after this run. The #PCManiacs do though. 24% in $VRNA. Tik tok on the M&A clock ⏰ $xbi $ibb.
3
1
21
I don’t really have a dog in the $srpt fight. Never thought the DMD therapies worked, so have stayed away from the stock and following the story closely. Two observations though:. The way management has communicated recently has been inappropriate and potentially unethical. Doug.
12
5
55
Scarcity value of $gern rises?.
$BMY Phase 3 INDEPENDENCE Trial for Reblozyl in Adult Patients with Myelofibrosis-Associated Anemia Did Not Meets its Primary Endpoint.
0
2
8
$jnj discovering that investors like their portfolio companies to grow. $MRK found the files in the computer last week. Who’s going to follow suit next? $xbi $ibb.
$JNJ understood the homework assignment and answered question #4 in prior post. Their work isn't done but it's clear mgmt believes in strategic merits of becoming a category leader in psychiatry. Adolescents, for a variety of reasons, are developing mood disorders at an alarming
1
1
2
$srrk no need for equity financing pro forma for (hypothetical) PRV sale + credit facility… given no intention (standalone) of larger cardio-esque trials. Probably a bolus of patients up front given market well understood . Not going to get platform-like valuation like $AVXS at.
0
1
14
Talk to me $mtsr 🪿.
This is very compelling slide from $mtsr deck. $vktx $amgn $nvo $vktx $lly $rhhby . believe orfo is in same ballpark as MET-224 on API/yr (~1,300mg / yr). key takeaway: $mtsr might be primed for a cult following like the #PCManiacs and / or $vktx $xbi $ibb $bbc
2
1
6
You’re hearing it here first; $MRK + $VRNA + $INSM = $110 / sh for $MRK by YE 2025. Can spin $Insm gene therapy pipeline, give Will Lewis a new project.
$mrk Now the clock starts ticking to the 3 year mark. Cost of capital continuing to rise due to increased pipeline risk . If mgmt doesn’t do something prior to 2Q earnings on 29-July and gives us same old $1bn to $15bn dance, while, in background, Gardasil isn’t resolved and Dean.
1
1
10
It might finally be your time $cytk . run with the lions and tigers and bears $xbi $ibb.
1
0
14
Analyst asked on $mrk $vrna call “why do this deal now?”. Tough to be upset with mgmt for not doing deals when some of the covering analysts don’t understand why they need to do deals with urgency.
25% in $vrna today into the close. Lot of noise the last few months, but one thing hasn’t changed. Pharma has a math problem and $vrna is uniquely positioned to solve some of it. If true, good move by $MRK. Stock should start to resume upward momentum. To Rob Davis: We can work.
0
0
2
$vrna hasn’t lost that loving feel yet. Feels like some re-balancing / re-positioning in name after a banner year. Still a potential 2-bagger on just ensi nebulizer in COPD. Call options still in bronchiectasis and asthma.
Talk to me $vrna 🪿.
0
0
8
This would be cathartic for biotech and the #PCManiacs $mrk $vktx.
The probability of $MRK buying $VKTX is 99.9%. They may not want to, but they don’t really have a choice.
1
1
9
RT @capitalemployed: 42 Investment Ideas (Crowdsourced from X/Substack) 💡. Thanks to all those who contributed. @….
0
12
0
$Azn on track to displace the complacent / current king of oncology $MRK with $smmt partnership.
0
0
3
$ptgx welcome to the world of obesity-induced stock px volatility. SAE of having pipeline in largest market ever $xbi $ibb.
2
0
4
$nktr is a tough one given the ongoing financing overhang. Going for $100mm+ today and then they’ll have to do it piecemeal here / post-AA data. Will need another $500 to $750mm to just get to commercial (depending on cash cushion you model). Very tough to be a beaten down bio in.
$Nktr of course they want to partner, but need to raise a bolus of cash in interim. More than 50% of MC pre-AA data.
1
0
5
$mrk Now the clock starts ticking to the 3 year mark. Cost of capital continuing to rise due to increased pipeline risk . If mgmt doesn’t do something prior to 2Q earnings on 29-July and gives us same old $1bn to $15bn dance, while, in background, Gardasil isn’t resolved and Dean.
On Monday, $MRK will be 1280 days from Keytruda LOE. In layman’s terms, that is 3.5 years. While mgmt will argue that Keytruda LOE will be a hill not a cliff, precedents suggest that LOE roll-offs do not get valuation credit. This situation is no different and perhaps much more.
1
0
7
What’s happening in $vera last few days?.
@TheBiotechBear @TraderNorway @TTRAmyloid Proteinuria reduction measured at various time points so not sure you can really run cross trial comparisons if idea is proteinuria reduction is linear over time and they are all probably stabilizing eGFR. $vera at 36 weeks.$otsky at 39 weeks.$nvs and $vrtx at 48 weeks. With that.
0
0
1